Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas
Overview
Authors
Affiliations
Epigenetics is involved in tumor progression and drug resistance in human colorectal carcinoma (CRC). This study addressed the hypothesis that the DNA methylation profiling may predict the clinical behavior of metastatic CRCs (mCRCs). The global methylation profile of two human mCRC subgroups with significantly different outcome was analyzed and compared with gene expression and methylation data from The Cancer Genome Atlas COlon ADenocarcinoma (TCGA COAD) and the NCBI GENE expression Omnibus repository (GEO) GSE48684 mCRCs datasets to identify a prognostic signature of functionally methylated genes. A novel epigenetic signature of eight hypermethylated genes was characterized that was able to identify mCRCs with poor prognosis, which had a CpG-island methylator phenotype (CIMP)-high and microsatellite instability (MSI)-like phenotype. Interestingly, methylation events were enriched in genes located on the q-arm of chromosomes 13 and 20, two chromosomal regions with gain/loss alterations associated with adenoma-to-carcinoma progression. Finally, the expression of the eight-genes signature and MSI-enriching genes was confirmed in oxaliplatin- and irinotecan-resistant CRC cell lines. These data reveal that the hypermethylation of specific genes may provide prognostic information that is able to identify a subgroup of mCRCs with poor prognosis.
Liu B, Xie Y, Zhang Y, Tang G, Lin J, Yuan Z Cell Biosci. 2025; 15(1):7.
PMID: 39844296 PMC: 11756021. DOI: 10.1186/s13578-024-01337-y.
Tian S, Chen M Front Pharmacol. 2024; 15:1466156.
PMID: 39268463 PMC: 11391208. DOI: 10.3389/fphar.2024.1466156.
Li Y, Li X, Wu B, Su S, Su Y, Guo L Front Mol Biosci. 2024; 11:1424104.
PMID: 39170745 PMC: 11335499. DOI: 10.3389/fmolb.2024.1424104.
Yuan T, Wankhede D, Edelmann D, Kather J, Tagscherer K, Roth W EBioMedicine. 2024; 105:105223.
PMID: 38917511 PMC: 11255517. DOI: 10.1016/j.ebiom.2024.105223.
Fei Y, Cao D, Dong R, Li Y, Wang Z, Gao P Clin Transl Oncol. 2024; 26(10):2718-2737.
PMID: 38703335 DOI: 10.1007/s12094-024-03495-4.